Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025)

Tyra Biosciences has reported Total Non-Current Liabilities for 6 years, with the latest figure at $23.4 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 14.84% year-over-year to $23.4 million; the trailing twelve-month figure through Dec 2025 stood at $23.4 million (up 14.84% YoY), and the FY2025 full-year result was $23.4 million, up 14.84% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $23.4 million, up from $21.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $23.4 million in Q4 2025, with the low at $4.6 million in Q4 2021.
• Historically, Total Non-Current Liabilities has averaged $14.0 million across 5 years, with a median of $15.5 million in 2023.
• The largest YoY upside for Total Non-Current Liabilities was 163.34% in 2023 against a maximum downside of 18.15% in 2023.
• Tyra Biosciences' Total Non-Current Liabilities stood at $4.6 million in 2021, then surged by 78.01% to $8.2 million in 2022, then surged by 163.34% to $21.5 million in 2023, then retreated by 5.31% to $20.4 million in 2024, then rose by 14.84% to $23.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $23.4 million (Q4 2025), $21.3 million (Q3 2025), and $19.4 million (Q2 2025), per Business Quant data.